Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AB Science

AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease
From AB Science
Via GlobeNewswire
AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch
From AB Science
Via GlobeNewswire
AB Science today provides an update on its masitinib platform
From AB Science
Via GlobeNewswire
AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
From AB Science
Via GlobeNewswire
AB Science will participate in the Biomed Forum investors conference
From AB Science
Via GlobeNewswire
AB Science provides a summary of the webcast held on December 16, 2024
From AB Science
Via GlobeNewswire
AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET
From AB Science
Via GlobeNewswire
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease
From AB Science
Via GlobeNewswire
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
From AB Science
Via GlobeNewswire
AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
From AB Science
Via GlobeNewswire
AB Science announces a slight delay in the publication of its 2024 half-year financial report
From AB Science
Via GlobeNewswire
AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
From AB Science
Via GlobeNewswire
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
From AB Science
Via GlobeNewswire
AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19
From AB Science
Via GlobeNewswire
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
From AB Science
Via GlobeNewswire
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
From AB Science
Via GlobeNewswire
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
From AB Science
Via GlobeNewswire
AB Science reports its revenues for the year 2023 and provides an update on its activities
From AB Science
Via GlobeNewswire
AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036
From AB Science
Via GlobeNewswire
AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient
From AB Science
Via GlobeNewswire
AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
From AB Science
Via GlobeNewswire
AB Science announces a slight delay in the publication of its 2023 annual financial report
From AB Science
Via GlobeNewswire
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
From AB Science
Via GlobeNewswire
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
From AB Science
Via GlobeNewswire
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
From AB Science
Via GlobeNewswire
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
From AB Science
Via GlobeNewswire
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
From AB Science
Via GlobeNewswire
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
From AB Science
Via GlobeNewswire
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
From AB Science
Via GlobeNewswire
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
From AB Science
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.